dicyclopentyl-acetic acid | 55640-02-3

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: dicyclopentyl-acetic acid
• 英文别名: Dicyclopentyl-essigsaeure；2,2-Dicyclopentylaceticacid；2,2-dicyclopentylacetic acid
• CAS: 55640-02-3
• 化学式: C₁₂H₂₀O₂
• 分子量: 196.29
• InChiKey: POLWQCHLQLJPDW-UHFFFAOYSA-N

物化性质

• 熔点：
  59-60 °C
• 沸点：
  150-152 °C(Press: 0.3 Torr)
• 密度：
  1.089±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  4.2
• 重原子数：
  14
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.92
• 拓扑面积：
  37.3
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  dicyclopentyl-acetic acid 在 五氯化磷 作用下， 生成 dicyclopentyl-acetyl chloride
  参考文献：
  名称：

  v. Braun, Chemische Berichte, 1934, vol. 67, p. 218,224

  摘要：

  DOI：
• 作为产物：
  描述：

  dicyclopentyl-malonic acid diethyl ester 在 盐酸 、 氢氧化钾 作用下， 生成 dicyclopentyl-acetic acid
  参考文献：
  名称：

  v. Braun; Fischer, Chemische Berichte, 1933, vol. 66, p. 101,103

  摘要：

  DOI：

文献信息

• CATALYST FOR ASYMMETRIC HYDROGENATION
  申请人：MAEDA Hironori

  公开号：US20100324338A1

  公开（公告）日：2010-12-23

  This invention aims at providing a catalyst for producing an optically active aldehyde or an optically active ketone, which is an optically active carbonyl compound, by carrying out selective asymmetric hydrogenation of an α,β-unsaturated carbonyl compound, particularly a catalyst which is insoluble in a reaction mixture for obtaining optically active citronellal which is useful as a flavor or fragrance, by carrying out selective asymmetric hydrogenation of citral, geranial or neral; and a method for producing a corresponding optically active carbonyl compound. The invention relates to a catalyst for asymmetric hydrogenation of an α,β-unsaturated carbonyl compound, which comprises a powder of at least one metal selected from metals belonging to Group 8 to Group 10 of the Periodic Table, or a metal-supported substance in which at least one metal selected from metals belonging to Group 8 to Group 10 of the Periodic Table is supported on a support, an optically active cyclic nitrogen-containing compound and an acid.

  这项发明旨在通过对α，β-不饱和羰基化合物进行选择性不对称加氢，特别是通过对柠檬醛、香叶醛或柠檬醛进行选择性不对称加氢，从而提供用作香料或香精的有用的光学活性香茅醛的催化剂，该香茅醛是一种光学活性羰基化合物；以及生产相应的光学活性羰基化合物的方法。该发明涉及一种用于不对称加氢α，β-不饱和羰基化合物的催化剂，其包括来自周期表第8至第10族金属中至少一种金属的粉末，或者至少一种来自周期表第8至第10族金属的金属负载物质，该金属负载在一种支撑物上，还包括光学活性的含氮环化合物和酸。
• METHOD FOR MANUFACTURING OPTICALLY ACTIVE MENTHOL
  申请人：Tsuda Toshiro

  公开号：US20130253228A1

  公开（公告）日：2013-09-26

  An object of the present invention is to provide a method for manufacturing an optically active menthol having fewer steps, which generates less environmentally polluting waste because a catalytic reaction is involved in all of the steps, and is capable of saving a production cost. The present invention relates to a method for manufacturing an optically active menthol, including the following steps: A-1) asymmetrically hydrogenating at least one of geranial and neral to thereby obtain an optically active citronellal, B-1) conducting a ring-closure reaction of the optically active citronellal in the presence of an acid catalyst to thereby obtain an optically active isopulegol, and C-1) hydrogenating the optically active isopulegol to thereby obtain an optically active menthol.

  本发明的目的是提供一种制造具有较少步骤的光学活性薄荷醇的方法，因为所有步骤都涉及催化反应，所以产生的环境污染废物较少，并且能够节省生产成本。本发明涉及一种制造光学活性薄荷醇的方法，包括以下步骤：A-1）不对称地氢化至少一种香叶醛和柠檬醛以获得光学活性柠檬醛，B-1）在酸催化剂存在下对光学活性柠檬醛进行环闭合反应，从而获得光学活性异薄荷醇，以及C-1）对光学活性异薄荷醇进行氢化以获得光学活性薄荷醇。
• INSOLUBLE INSULIN COMPOSITIONS
  申请人：ELI LILLY AND COMPANY

  公开号：EP0911035A2

  公开（公告）日：1999-04-28

  The present invention relates to insoluble compositions containing acylated proteins selected from the group consisting of acylated insulin, acylated insulin analog, and acylated proinsulin, and formulations thereof. The formulations are suitable for parenteral delivery or other means of delivery, to a patient for extended control of blood glucose levels. More particularly, the present invention relates to compositions comprised of an acylated protein complexed with zinc, protamine, and a phenolic compound such that the resulting microcrystal is analogous to the neutral protamine Hagedorn (NPH) insulin crystal form. Surprisingly, it has been discovered that compositions of such acylated proteins have therapeutically superior subcutaneous release pharmacokinetics, and more extended and flatter glucodynamics, than presently available commercial preparations of NPH insulin. Yet, the present crystals retain certain advantageous properties of NPH crystals, being readily able to be resuspended and also mixable with soluble insulins.

  本发明涉及含有选自由酰化胰岛素、酰化胰岛素类似物和酰化原胰岛素组成的组中的酰化蛋白质的不溶性组合物及其制剂。这些制剂适用于肠道外给药或以其他方式给药，以延长对患者血糖水平的控制。更具体地说，本发明涉及一种由酰化蛋白质与锌、原胺和酚类化合物络合而成的组合物，由此产生的微晶类似于中性原胺哈格多恩（NPH）胰岛素晶型。令人惊奇的是，人们发现这种酰化蛋白质的组合物与目前市售的 NPH 胰岛素商业制剂相比，具有更优越的皮下释放药代动力学和更持久、更平稳的血糖动力学。然而，目前的晶体仍保留了 NPH 晶体的某些有利特性，易于重新悬浮，也可与可溶性胰岛素混合。
• Insoluble compositions for controlling blood glucose
  申请人：ELI LILLY AND COMPANY

  公开号：EP0925792A2

  公开（公告）日：1999-06-30

  The present invention relates to insoluble compositions comprising a protein selected from the group consisting of insulin, insulin analogs, and proinsulins; a derivatized protein selected from the group consisting of derivatized insulin, derivatized insulin analog, and derivatized proinsulin; a complexing compound; a hexamer-stabilizing compound; and a divalent metal cation. Formulations of the insoluble composition are suitable for both parenteral and non-parenteral delivery for treating hyperglycemia and diabetes. Microcrystal forms of the insoluble precipitate are pharmaceutically analogous to the neutral protamine Hagedorn (NPH) insulin crystal form. Surprisingly, it has been discovered that suspension formulations of such insoluble compositions possess unique and controllable dissolution properties that provide therapeutically advantageous glucodynamics compared with insulin NPH formulations.

  本发明涉及不溶性组合物，该组合物包含选自由胰岛素、胰岛素类似物和原胰岛素组成的组的蛋白质；选自由衍生化胰岛素、衍生化胰岛素类似物和衍生化原胰岛素组成的组的衍生化蛋白质；复合物；六聚体稳定化合物；以及二价金属阳离子。不溶性组合物的制剂既适用于肠道外给药，也适用于治疗高血糖和糖尿病的非肠道外给药。不溶性沉淀物的微晶形式在药学上类似于中性原明哈格登（NPH）胰岛素晶体形式。令人惊奇的是，人们发现这种不溶性组合物的悬浮制剂具有独特的可控溶解特性，与 NPH 胰岛素制剂相比，这种悬浮制剂具有治疗上有利的血糖动力学特性。
• Insoluble Insulin Compositions for Controlling Blood Glucose
  申请人：Eli Lilly & Company

  公开号：EP1396272A1

  公开（公告）日：2004-03-10

  The present invention relates to insoluble compositions comprising a protein selected from the group consisting of insulin, insulin analogs, and proinsulins; a derivatized protein selected from the group consisting of derivatized insulin, derivatized insulin analog, and derivatized proinsulin; a complexing compound; a hexamer-stabilizing compound; and a divalent metal cation. Formulations of the insoluble composition are suitable for both parenteral and non-parenteral delivery for treating hyperglycemia and diabetes. Microcrystal forms of the insoluble precipitate are pharmaceutically analogous to the neutral protamine Hagedorn (NPH) insulin crystal form. Surprisingly, it has been discovered that suspension formulations of such insoluble compositions possess unique and controllable dissolution properties that provide therapeutically advantageous glucodynamics compared with insulin NPH formulations.

  本发明涉及不溶性组合物，该组合物包含选自由胰岛素、胰岛素类似物和原胰岛素组成的组的蛋白质；选自由衍生化胰岛素、衍生化胰岛素类似物和衍生化原胰岛素组成的组的衍生化蛋白质；复合物；六聚体稳定化合物；以及二价金属阳离子。不溶性组合物的制剂既适用于肠道外给药，也适用于治疗高血糖和糖尿病的非肠道外给药。不溶性沉淀物的微晶形式在药学上类似于中性原明哈格登（NPH）胰岛素晶体形式。令人惊奇的是，人们发现这种不溶性组合物的悬浮制剂具有独特的可控溶解特性，与 NPH 胰岛素制剂相比，这种悬浮制剂具有治疗上有利的血糖动力学特性。